Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q1 2022 Earnings Presentation
17 slides from Arcticzymes Technologies Asa's earnings presentation, 2022
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights - Q1 2022 2 Business Update 3 Financials 4 Outlook 2022 and Beyond
Slide 3: Highlights
Highlights
Slide 4: Highlights Q1 2022
Highlights Q1 2022 Achieved an outstanding quarterly performance Best ever quarterly Highest quarterly AZT expands sales for sales ever activities into Oslo at Biomanufacturing 49.2 MNOK ShareLab and Molecular Tools New OEM supply Strong EBITDA agreement with performance global License 27.9 MNOK Sci
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Commercial Sales
Business Updates Commercial Sales Biomanufacturing Molecular Tools (Research & Diagnostics) ✓ Best-ever quarterly sales 18.8 MNOK ✓ Best-ever quarterly sales 30.4 MNOK ✓ Accounts for 38% of total Q1 sales ✓ Accounts for 62% of total Q1 sales ✓ Experiencing an upturn in sales following pandemic ✓ Res
Slide 7: Business Update: Innovations
Business Update Innovations Establishing a new applications laboratory at ShareLab in Oslo ShareLab is a service platform provider of laboratory and office facilities to biotechnology companies It will support application development activities to demonstrate the utility of AZT´s enzymes in customer
Slide 8: Business Update: Operations
Business Update Operations New production facilities Fully operational with all production processes transferred Support all future manufacturing Customer audits New “common" fermentation room Three customers conducted cGMP audits of the Company and new production facilities One of the audits was th
Slide 9: Business Updates: Strategic Growth Initiatives
Business Updates Strategic Growth Initiatives AZT remains committed to execute on its strategic growth initiatives Organic growth Ongoing recruitment drive to strengthening the organisation cross functionally Greater competences/support in quality and cGMP product development and commercialisation a
Slide 10: Financials
Financials
Slide 11: ArcticZymes Sales Q1 2022
ArcticZymes Sales Q1 2022 Trend from last two years has changed Sales per commercial business Sales increase of 20 % compared to same 50 000 quarter last year 45 000 Biomanufacturing Molecular Tools Achieved 49.2 MNOK (40.9 MNOK) 40 000 Currency had an estimated 0.6 MNOK 35 000 positive impact on un
Slide 12: 12 Month rolling average quarterly sales
12 Month rolling average quarterly sales Growth trend continues in 2022 40 Sales development 35 Sales development ex Covid-19 30 25 MNOK 20 15 10 5 0 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 12 *not reporting on Covid-19 sales separately
Slide 13: Profitability and expenses
Profitability and expenses Investments in organic growth influences our figures 60 Sales EBITDA Quarterly Sales (MNOK 49.2 vs. 40.9) 50 40 EBITDA increased by 2.1 MNOK (MNOK 27.9 vs 25.8) MNOK 30 20 Expenses increased by 5.6 MNOK Increase in personnel as we invest in 10 organic growth 0 Increase in
Slide 14: Cash Flow
Cash Flow 14 MNOK in positive cash flow Amounts in NOK 1.000' 220 30 Net Cash (MNOK) Changes in Cash (MNOK) 210 25 Changes in cash (MNOK) 200 Net Cash (MNOK) 20 190 15 180 10 170 5 160 150 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 14
Slide 15: Outlook
Outlook
Slide 16: Outlook 2022 and Beyond
Outlook 2022 and Beyond Annual Sale Target Remains unchanged 32% The Company outlook for 2022 achieved Annual sales target of NOK 155 million Quarterly fluctuations will continue Lower contribution from coronavirus-related sales Quarterly Rolling 12 Month Sales Expanded innovation activities into th
Slide 17: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q1 2022 Earnings Presentation on 6ix